This study highlights a key innovation in AKI therapy by leveraging CXCR4 targeting for precise micro-environmental intervention, where the C-CS carrier not only enhances renal siRNA delivery, but also improves cellular uptake through receptor-mediated endocytosis. The gene discussed is CXCR4; the disease is acute kidney injury.